Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis
We evaluated the potential cardiovascular risk protection of bilirubin in hemodialysis (HD) patients. An enlarged set of studies were evaluated in 191 HD patients, including hematological study, lipid profile, iron metabolism, nutritional, inflammatory markers, and dialysis adequacy. The TA duplicat...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2014/175286 |
id |
doaj-dce8018d4ce640b6bfe2b272d0e53041 |
---|---|
record_format |
Article |
spelling |
doaj-dce8018d4ce640b6bfe2b272d0e530412020-11-24T21:42:12ZengHindawi LimitedBioMed Research International2314-61332314-61412014-01-01201410.1155/2014/175286175286Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under HemodialysisMaria do Sameiro-Faria0Michaela Kohlova1Sandra Ribeiro2Petronila Rocha-Pereira3Laetitia Teixeira4Henrique Nascimento5Flávio Reis6Vasco Miranda7Elsa Bronze-da-Rocha8Alexandre Quintanilha9Luís Belo10Elísio Costa11Alice Santos-Silva12Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalInstituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Rua do Campo Alegre 823, 4150-180 Porto, PortugalInstituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalIBILI, Faculdade de Medicina, Universidade de Coimbra, Azinhaga Santa Comba, Celas, 3000-548 Coimbra, PortugalFrenesius Medical Care, Nephrocare Maia, SA, Rua Altos 70, Maia, 4470-235 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalInstituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLaboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalWe evaluated the potential cardiovascular risk protection of bilirubin in hemodialysis (HD) patients. An enlarged set of studies were evaluated in 191 HD patients, including hematological study, lipid profile, iron metabolism, nutritional, inflammatory markers, and dialysis adequacy. The TA duplication screening in the UDP-glucuronosyltransferase 1 A1 (UGT1A1) promoter region was also performed. The UGT1A1 genotype frequencies in HD patients were 49.2%, 42.4%, and 8.4% for 6/6, 6/7, and 7/7 genotypes, respectively. Although no difference was found in UGT1A1 genotype distribution between the three tertiles of bilirubin, significant differences were found with increasing bilirubin levels, namely, a decrease in platelet, leukocyte, and lymphocyte counts, transferrin, oxidized low-density lipoprotein (ox-LDL), ox-LDL/low-density lipoprotein cholesterol ratio, apolipoprotein (Apo) A, Apo B, and interleukin-6 serum levels and a significant increased concentration of hemoglobin, hematocrit, erythrocyte count, iron, transferrin saturation, Apo A/Apo B ratio, adiponectin, and paraoxonase 1 serum levels. After adjustment for age these results remained significant. Our data suggest that higher bilirubin levels are associated with beneficial effects in HD patients, by improving lipid profile and reducing the inflammatory grade, which might contribute to increase in iron availability. These results suggest a potential cardiovascular risk protection of bilirubin in HD patients.http://dx.doi.org/10.1155/2014/175286 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maria do Sameiro-Faria Michaela Kohlova Sandra Ribeiro Petronila Rocha-Pereira Laetitia Teixeira Henrique Nascimento Flávio Reis Vasco Miranda Elsa Bronze-da-Rocha Alexandre Quintanilha Luís Belo Elísio Costa Alice Santos-Silva |
spellingShingle |
Maria do Sameiro-Faria Michaela Kohlova Sandra Ribeiro Petronila Rocha-Pereira Laetitia Teixeira Henrique Nascimento Flávio Reis Vasco Miranda Elsa Bronze-da-Rocha Alexandre Quintanilha Luís Belo Elísio Costa Alice Santos-Silva Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis BioMed Research International |
author_facet |
Maria do Sameiro-Faria Michaela Kohlova Sandra Ribeiro Petronila Rocha-Pereira Laetitia Teixeira Henrique Nascimento Flávio Reis Vasco Miranda Elsa Bronze-da-Rocha Alexandre Quintanilha Luís Belo Elísio Costa Alice Santos-Silva |
author_sort |
Maria do Sameiro-Faria |
title |
Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis |
title_short |
Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis |
title_full |
Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis |
title_fullStr |
Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis |
title_full_unstemmed |
Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis |
title_sort |
potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2014-01-01 |
description |
We evaluated the potential cardiovascular risk protection of bilirubin in hemodialysis (HD) patients. An enlarged set of studies were evaluated in 191 HD patients, including hematological study, lipid profile, iron metabolism, nutritional, inflammatory markers, and dialysis adequacy. The TA duplication screening in the UDP-glucuronosyltransferase 1 A1 (UGT1A1) promoter region was also performed. The UGT1A1 genotype frequencies in HD patients were 49.2%, 42.4%, and 8.4% for 6/6, 6/7, and 7/7 genotypes, respectively. Although no difference was found in UGT1A1 genotype distribution between the three tertiles of bilirubin, significant differences were found with increasing bilirubin levels, namely, a decrease in platelet, leukocyte, and lymphocyte counts, transferrin, oxidized low-density lipoprotein (ox-LDL), ox-LDL/low-density lipoprotein cholesterol ratio, apolipoprotein (Apo) A, Apo B, and interleukin-6 serum levels and a significant increased concentration of hemoglobin, hematocrit, erythrocyte count, iron, transferrin saturation, Apo A/Apo B ratio, adiponectin, and paraoxonase 1 serum levels. After adjustment for age these results remained significant. Our data suggest that higher bilirubin levels are associated with beneficial effects in HD patients, by improving lipid profile and reducing the inflammatory grade, which might contribute to increase in iron availability. These results suggest a potential cardiovascular risk protection of bilirubin in HD patients. |
url |
http://dx.doi.org/10.1155/2014/175286 |
work_keys_str_mv |
AT mariadosameirofaria potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT michaelakohlova potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT sandraribeiro potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT petronilarochapereira potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT laetitiateixeira potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT henriquenascimento potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT flavioreis potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT vascomiranda potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT elsabronzedarocha potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT alexandrequintanilha potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT luisbelo potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT elisiocosta potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis AT alicesantossilva potentialcardiovascularriskprotectionofbilirubininendstagerenaldiseasepatientsunderhemodialysis |
_version_ |
1725918373160681472 |